Hepatitis B Virus News and Research

RSS

GenMark receives non-exclusive license to Innogenetics' HCV genotyping patent estate

GenMark Diagnostics, Inc. a provider of automated, multiplex molecular diagnostic testing systems, announced today that it has acquired a non-exclusive license to Innogenetics' Hepatitis C Virus (HCV) genotyping patent estate for the United States.

3 Nov 2010

Inhibitex to present INX-189 data for HCV infections at AASLD Meeting

Inhibitex, Inc. announced today that three posters describing preclinical data on INX-189, the Company's nucleotide polymerase inhibitor in clinical development for the treatment of chronic hepatitis C (HCV) infections, will be presented by various scientists from the Company at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA.

2 Nov 2010

ADVANCE Phase 3 study confirms clinical benefits of telaprevir regimen in patients with HCV infection

The Phase 3 results from the ADVANCE study confirm the clinical benefits of telaprevir-based combination therapy regimens. The study reports an improvement in treatment discontinuation rates due to adverse events compared to Phase 2 studies, and demonstrates an increase in sustained viral response (SVR) in patients with hepatitis C virus (HCV). The primary endpoint for this study was SVR 24 weeks after last treatment.

2 Nov 2010

Boceprevir combinational therapy improves SVR rate in patients with HCV genotype 1

The final results of the RESPOND-2 trial demonstrated that combination therapy with Boceprevir yields higher sustained virologic response (SVR) rates for patients with hepatitis C virus (HCV) genotype 1 who did not respond to or relapsed after treatment with peginterferon alpha 2b and Ribavirin.

2 Nov 2010

Telbivudine prevents HBV transmission from mothers to newborns: Study

Researchers studied the treatment of pregnant women with hepatitis B virus (HBV) with Telbivudine in their second to third trimesters. The study concluded that both the mothers benefited from treatment and no transmission of HBV to newborns was detected at 28 weeks postbirth.

1 Nov 2010

Valeant, Kadmon enter strategic agreement for taribavirin and ribavirin

Valeant Pharmaceuticals International, Inc. and Kadmon Pharmaceuticals LLC have concluded two strategic agreements for the development and commercialization of taribavirin and the commercial marketing of ribavirin in the treatment of viral diseases, including hepatitis C virus (HCV).

1 Nov 2010

Inhibitex announces initiation of INX-189 Phase 1b clinical trial for HCV infection

Inhibitex, Inc. announced today that it has initiated a Phase 1b, multiple ascending dose (MAD) clinical trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic infections caused by hepatitis C virus (HCV).

1 Nov 2010

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced the results of a Week-24 planned interim analysis of the Phase 2 response-guided PILLAR study for TMC435, Medivir's key pipeline asset, a hepatitis C protease inhibitor dosed once-daily.

1 Nov 2010

Merck's boceprevir improves SVR rate in adults with chronic hepatitis C virus genotype 1 infection

Merck reported today that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, demonstrated significantly higher sustained virologic response (SVR) rates in adult patients who previously failed treatment (treatment-failure; HCV RESPOND-2) and in adult patients who were new to treatment for chronic hepatitis C virus (HCV) genotype 1 compared to control, the primary objective of the studies.

1 Nov 2010

Study determines long-term clinical outcome of patients posttransplant after anitviral therapy

Researchers from the University of Bari, Italy, concluded that treating patients after transplantation with antiviral therapy creates a sustained viral response (SVR) and protects them from liver-related deaths. The purpose of this study was to determine the long-term clinical outcomes of patients posttransplant who underwent antiviral therapy for recurrent hepatitis C virus (HCV) infection of the liver graft.

1 Nov 2010

Boehringer to present data of SOUND-C1 Phase Ib study for HCV treatment at AASLD Meeting

Boehringer Ingelheim announced results from a Phase Ib study, SOUND-C1, that showed the combination of two oral hepatitis C virus (HCV) compounds, the protease inhibitor BI 201335 and the polymerase inhibitor BI 207127, with ribavirin reduced viral load to the lower limit of quantifiable levels in HCV treatment-naïve patients.

1 Nov 2010

Idera presents IMO-2125 Phase 1 clinical trial data for HCV infection at AASLD Meeting

Idera Pharmaceuticals, Inc. announced today the presentation of data from a Phase 1 clinical trial evaluating IMO-2125, a novel immune modulator, in null-responder patients with chronic hepatitis C virus (HCV) infection.

1 Nov 2010

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Tibotec Pharmaceuticals announced today the company will present the results of a Week-24 planned interim analysis of the phase 2 response-guided PILLAR study in treatment-naive patients with chronic genotype 1 hepatitis C virus (HCV) at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA., USA. The data will be presented as part of a late-breaker oral presentation on Monday, November 1.

1 Nov 2010

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.

1 Nov 2010

Gilead presents Phase IIa data for HCV therapy at The Liver Meeting 2010

Gilead Sciences, Inc. today announced data from a Phase IIa study showing that its investigational compounds GS 9190 and GS 9256, used in conjunction with current standard of care therapies, produced substantial suppression of the hepatitis C virus (HCV) within 28 days of treatment.

1 Nov 2010

Presidio to present PPI-461 data for HCV infection at AASLD meeting

Presidio Pharmaceuticals, Inc. announced today that Nathaniel Brown, M.D., Chief Medical Officer, will present a late-breaker poster, "Safety and Pharmacokinetics of PPI-461, a Potent New Hepatitis C virus (HCV) NS5A Inhibitor with Pan-Genotype Activity" at the 61st AASLD meeting in Boston, MA, on November 1, 2010.

30 Oct 2010

Cancer researcher to receive 2010 AACR Award of excellence

John D. Groopman, Ph.D., has been selected to receive the 2010 American Association for Cancer Research-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research

26 Oct 2010

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called OPTIMIZE that will evaluate twice-daily (BID) dosing of a telaprevir-based combination regimen in people chronically infected with genotype 1 hepatitis C virus (HCV) who have not been treated previously. This is the first Phase 3 study to evaluate twice-daily dosing of a protease inhibitor for the treatment of hepatitis C. OPTIMIZE will not include a control arm of pegylated-interferon and ribavirin alone.

26 Oct 2010

Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV

Intercell AG and Romark Laboratories L.C. today announced plans to commence clinical trials of Intercell's investigational therapeutic Hepatitis C virus (HCV) vaccine, IC41, in combination with Romark's antiviral drug, nitazoxanide, during the first half of 2011.

21 Oct 2010

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Abbott today announced financial results for the third quarter ended Sept. 30, 2010.

20 Oct 2010

Hepatitis B Virus News and Research

GenMark receives non-exclusive license to Innogenetics' HCV genotyping patent estate

Inhibitex to present INX-189 data for HCV infections at AASLD Meeting

ADVANCE Phase 3 study confirms clinical benefits of telaprevir regimen in patients with HCV infection

Boceprevir combinational therapy improves SVR rate in patients with HCV genotype 1

Telbivudine prevents HBV transmission from mothers to newborns: Study

Valeant, Kadmon enter strategic agreement for taribavirin and ribavirin

Inhibitex announces initiation of INX-189 Phase 1b clinical trial for HCV infection

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

Merck's boceprevir improves SVR rate in adults with chronic hepatitis C virus genotype 1 infection

Study determines long-term clinical outcome of patients posttransplant after anitviral therapy

Boehringer to present data of SOUND-C1 Phase Ib study for HCV treatment at AASLD Meeting

Idera presents IMO-2125 Phase 1 clinical trial data for HCV infection at AASLD Meeting

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

Gilead presents Phase IIa data for HCV therapy at The Liver Meeting 2010

Presidio to present PPI-461 data for HCV infection at AASLD meeting

Cancer researcher to receive 2010 AACR Award of excellence

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News